Share

April 2015; 2 (2) ArticleOpen Access

Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children

Yael Hacohen, Michael Absoud, Kumaran Deiva, Cheryl Hemingway, Petra Nytrova, Mark Woodhall, Jacqueline Palace, Evangeline Wassmer, Marc Tardieu, Angela Vincent, Ming Lim, Patrick Waters
First published March 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000081
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2671

Share

Article Information

vol. 2 no. 2 e81
DOI: 
https://doi.org/10.1212/NXI.0000000000000081
PubMed: 
25798445
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 9, 2014
  • Accepted in final form January 13, 2015
  • First Published March 12, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Yael Hacohen, MRCPCH,
    2. Michael Absoud, MRCPCH, PhD,
    3. Kumaran Deiva, MD, PhD,
    4. Cheryl Hemingway, MRCP, PhD,
    5. Petra Nytrova, MD,
    6. Mark Woodhall, PhD,
    7. Jacqueline Palace, MRCP, MD,
    8. Evangeline Wassmer, FRCPCH,
    9. Marc Tardieu, MD, PhD,
    10. Angela Vincent, FRS, FMedSci*,
    11. Ming Lim, MRCP, PhD* and
    12. Patrick Waters, PhD*
    13. On behalf of United Kingdom Childhood Inflammatory Demyelination (UK-CID) and French Kidbiosep Study Groups
  1. Yael Hacohen, MRCPCH,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and the University of Oxford

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Michael Absoud, MRCPCH, PhD,
    3. Scientific Advisory Boards:

    1. M Absoud serves on the data safety monitoring board for a study sponsored by Neurim Pharmaceuticals

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. M Absoud sits on the editorial advisory board of the International Journal of Language & Communication Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. M Absoud received funding from the MS Society and Action Medical Research Charities

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kumaran Deiva, MD, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen Idec, travel subsidies Merck Serono, travel subsidies

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Cheryl Hemingway, MRCP, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Biogen Idec honorarium speaker contract Terumo products honorarium speaker contract Merck Serono Bayer

    Editorial Boards:

    1. Journal of Paediatric Neurology editorial board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis society Action Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Petra Nytrova, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. PN received speaker honoraria from Biogen Idec and Novartis.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. PN, her research work is supported by the Czech Ministries of Education and Health (PRVOUK-P26/LF1/4).

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Mark Woodhall, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Jacqueline Palace, MRCP, MD,
    8. Scientific Advisory Boards:

    1. UK advisory board participant: 1) Merck Serono 2) Bayer Schering Pharma 3) Biogen Idec 4) Teva Pharmaceutical Industries Ltd. 5) Novartis Pharmaceuticals UK Ltd. 6) Sanofi-Aventis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Support for attending ECTRIMS Merck Serono Novartis and Biogen idec

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. In addition to advisory committees, consultant for: Ono Pharmaceuticals Ltd. Chugai Pharma Ltd. CI Consulting Biogen Idec GlaxoSmithKline

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Donations to support local service development and research, none relevant to the current work: Bayer Schering Merke Serono Novartis

    Research Support, Government Entities:

    1. Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MS Society UK Guthy Jackson Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Evangeline Wassmer, FRCPCH,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. commercial (Biogen, Teva, Genzyme), speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Attended meetings (CME) supported by many pharmaceutical companies. Received travel/accommodation/speaker honoraria to attend meetings from Shire, Biogen, Teva, Genzyme, UCB and Merck Serono.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Marc Tardieu, MD, PhD,
    10. Scientific Advisory Boards:

    1. 1. Scientific advisory board for Biogen, Genzyme and Novartis for new treatment in pediatric MS.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1. Travelling money for the meeting of the two scientific advisory board (two trips one in Boston one in London from Paris). One trip to Boston for Novartis advisory meeting.

    Editorial Boards:

    1. European J Paediatr Neurol (editorial board) Multiple sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Angela Vincent, FRS, FMedSci*,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Occasional small honoraria, travel and speaker honoraria from Baxter International Inc and Biogen Inc

    Editorial Boards:

    1. Advisory Editorial Board Neurology; Associate Editor for Brain ended 2013

    Patents:

    1. Hold patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG.

    Publishing Royalties:

    1. Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010). System in Children (Mac Keith Press, 2010)

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Ended 2014.

    Speakers' Bureaus:

    1. Scientific conference expenses only

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NIHR general support for antibody work

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Ming Lim, MRCP, PhD* and
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1)Travel grants from Merc Serono for attending meetings (non-profit)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultancy for advisory board meeting CSL Behring (non-profit entity)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Patrick Waters, PhD*
    13. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker honoraria from Biogen Idec Japan and Euroimmun AG.

    Editorial Boards:

    1. Frontiers in molecular innate immunity, Review editor, 1 Yr

    Patents:

    1. Assays for the detection of antibodies to lgi1, Caspr2 and tag-1.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. A patent has been submitted on GABAAR.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Nuffield Department of Clinical Neurosciences (Y.H., M.W., J.P., A.V., M.L., P.W.), John Radcliffe Hospital, University of Oxford, UK; Children's Neurosciences (M.A., M.L.), Evelina Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London, UK; Assistance Publique Hôpitaux de Paris (K.D., M.T.), Hopitaux Universitaires Paris Sud, France; Pediatric Neurology Department and National Referral Center for Neuroinflammatory Diseases (K.D., M.T.), Université Paris Sud, Le Kremlin-Bicêtre, Paris, France; Department of Paediatric Neurology (C.H.), Great Ormond Street Hospital for Children, London, UK; Department of Neurology and Center of Clinical Neuroscience (P.N.), General University Hospital in Prague, Czech Republic; First Faculty of Medicine (P.N.), Charles University in Prague, Czech Republic; and Department of Paediatric Neurology (E.W.), Birmingham Children's Hospital, UK.
  1. Correspondence to Dr. Lim: ming.lim{at}gstt.nhs.uk
View Full Text

Article usage

Article usage: March 2015 to April 2023

AbstractFullPdfSource
Mar 20151422628Highwire
Mar 201503325pmc
Apr 201524111255Highwire
Apr 201507352pmc
May 2015651624Highwire
May 201509363pmc
Jun 2015641728Highwire
Jun 201506831pmc
Jul 201572912Highwire
Jul 201504125pmc
Aug 20154848Highwire
Aug 201504423pmc
Sep 20154028Highwire
Sep 201504724pmc
Oct 20151755Highwire
Oct 201503216pmc
Nov 20152734Highwire
Nov 201506622pmc
Dec 201525115Highwire
Dec 201504621pmc
Jan 20163864Highwire
Jan 201603520pmc
Feb 20163188Highwire
Feb 201604426pmc
Mar 20162836Highwire
Mar 201602718pmc
Apr 20163214Highwire
Apr 201602812pmc
May 20163232Highwire
May 201603218pmc
Jun 20163147Highwire
Jun 201603625pmc
Jul 20162221Highwire
Jul 201603816pmc
Aug 20164102Highwire
Aug 201604714pmc
Sep 20162015Highwire
Sep 201603520pmc
Oct 20163043Highwire
Oct 201605214pmc
Nov 201627412Highwire
Nov 201608020pmc
Dec 20161908Highwire
Dec 201604016pmc
Jan 20171965Highwire
Jan 201709530pmc
Feb 20172141Highwire
Feb 201706322pmc
Mar 20172112Highwire
Mar 201708119pmc
Apr 201718145Highwire
Apr 2017144951pmc
May 201714203Highwire
May 2017186570pmc
Jun 201711156Highwire
Jun 2017144653pmc
Jul 201714143Highwire
Jul 2017124446pmc
Aug 201712135Highwire
Aug 2017115155pmc
Sep 201711113Highwire
Sep 2017157180pmc
Oct 201711144Highwire
Oct 2017105052pmc
Nov 201715184Highwire
Nov 201794648pmc
Dec 20175325Highwire
Jan 201812813Highwire
Feb 201852114Highwire
Mar 201844024Highwire
Apr 201834733Highwire
Apr 2018164348pmc
May 201845123Highwire
Jun 201814922Highwire
Jun 2018113032pmc
Jul 201855923Highwire
Aug 201843316Highwire
Aug 201862729pmc
Sep 201805923Highwire
Oct 201825418Highwire
Nov 2018810030Highwire
Dec 2018626031Highwire
Jan 2019315028Highwire
Feb 2019949027Highwire
Mar 2019947940Highwire
Apr 2019339018Highwire
May 2019617421Highwire
Jun 2019515939Highwire
Jul 2019915634Highwire
Aug 201965829Highwire
Sep 2019117625Highwire
Oct 201978622Highwire
Nov 201975629Highwire
Dec 201952524Highwire
Jan 202043629Highwire
Feb 202054526Highwire
Mar 202023626Highwire
Apr 202022819Highwire
May 202054120Highwire
Jun 202044310Highwire
Jul 20203155Highwire
Aug 20206227Highwire
Sep 2020818019Highwire
Oct 202085825Highwire
Nov 202074026Highwire
Dec 2020114115Highwire
Jan 202172818Highwire
Feb 202142118Highwire
Mar 2021104124Highwire
Apr 202174914Highwire
May 202174012Highwire
Jun 202184011Highwire
Jul 202173920Highwire
Aug 20214317Highwire
Sep 202162413Highwire
Oct 2021105627Highwire
Nov 202132424Highwire
Dec 202183817Highwire
Jan 20224207Highwire
Feb 202294217Highwire
Mar 202224613Highwire
Apr 202231386Highwire
May 202242310Highwire
Jun 202252510Highwire
Jul 202261224Highwire
Aug 20221220317Highwire
Sep 2022813418Highwire
Oct 202274512Highwire
Nov 2022119225Highwire
Dec 202253410Highwire
Jan 2023620410Highwire
Feb 20237418Highwire
Mar 2023104011Highwire
Apr 202361914Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles